trending Market Intelligence /marketintelligence/en/news-insights/trending/clznuhotzrqvluisxtqwpq2 content esgSubNav
In This List

Trillium skin cancer treatment receives US FDA's orphan drug status

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Trillium skin cancer treatment receives US FDA's orphan drug status

Trillium Therapeutics Inc. said its skin cancer treatment TTI-621 received the U.S. Food and Drug Administration's orphan drug designation.

The drug, being studied as a treatment for cutaneous T cell lymphoma, works by activating the patient's immune system after blocking the activity of CD47, a protein commonly found on the surface of cancer cells.

Cutaneous T cell lymphoma is a rare type of cancer that begins in the white blood cells and attacks the skin.

The orphan drug status will help expedite development of the Toronto-based company's drug. Once approved, the treatment will be eligible for seven years of market exclusivity.